<DOC>
	<DOCNO>NCT01100463</DOCNO>
	<brief_summary>The purpose research study see combine uracil ointment ( 1UO ) capecitabine ( Xeloda ) prevent Hand-Foot Syndrome . The study also see effect 1UO capecitabine may patient metastatic breast cancer .</brief_summary>
	<brief_title>Study 0.1 % Uracil Ointment ( 1UO ) Ointment Prevention Hand-Foot Syndrome</brief_title>
	<detailed_description>Capecitabine use treatment human breast cancer among human cancer . Following absorption , capecitabine convert enzymatically 5-fluorouracil ( 5-FU ) . The administration capecitabine 5-FU cause cutaneous toxicity know hand-foot syndrome ( HFS ) palmar-plantar erythrodysesthesia ( PPE ) . HFS progressive dose duration exposure 5-FU capecitabine . HFS characterize progressive redness crack hand foot . Currently , approve therapy HFS .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Females , least 18 year old Histologically cytologically confirm metastatic breast cancer You also ulceration open wound palm hand sol foot Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover Grade 1 better ( except alopecia ) adverse event due agent administer 2 week earlier . Use vitamin 6 , chronic use Cox2 inhibitor , use fulldose anti coagulant use nicotine patch . The complete list eligibility criterion . Please see study doctor information .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>HFS , Hand-Foot Syndrome , Capecitabine , Breast Cancer</keyword>
</DOC>